150 related articles for article (PubMed ID: 19236761)
21. [JAK2V617F mutation and p-STAT5 protein expression in peripheral blood cells of patients with myeloproliferative neoplasm and their relations with clinical features].
Chen YX; Li Y; Zhang LY; Liu X; Shan NN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1398-404. PubMed ID: 23257441
[TBL] [Abstract][Full Text] [Related]
22. JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.
Kanduła Z; Janowski M; Więckowska B; Paczkowska E; Lewandowski K
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4789-4803. PubMed ID: 36242602
[TBL] [Abstract][Full Text] [Related]
23. [MPLW515L point mutation in patients with myeloproliferative disease].
Xia J; Xu W; Zhang SJ; Fan L; Qiao C; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1421-4. PubMed ID: 19099657
[TBL] [Abstract][Full Text] [Related]
24. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?
Verstovsek S; Silver RT; Cross NC; Tefferi A
Leukemia; 2006 Nov; 20(11):2067. PubMed ID: 16990780
[No Abstract] [Full Text] [Related]
25. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera.
Tefferi A; Strand JJ; Lasho TL; Knudson RA; Finke CM; Gangat N; Pardanani A; Hanson CA; Ketterling RP
Leukemia; 2007 Sep; 21(9):2074-5. PubMed ID: 17476276
[No Abstract] [Full Text] [Related]
26. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis.
Guglielmelli P; Loscocco GG; Mannarelli C; Rossi E; Mannelli F; Ramundo F; Coltro G; Betti S; Maccari C; Ceglie S; Chiusolo P; Paoli C; Barbui T; Tefferi A; De Stefano V; Vannucchi AM
Blood Cancer J; 2021 Dec; 11(12):199. PubMed ID: 34897288
[TBL] [Abstract][Full Text] [Related]
27. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
[TBL] [Abstract][Full Text] [Related]
28. [The quantitative assay and clinical significance of JAK2V617F mutation in 131 patients with chronic myeloproliferative disorders].
Shen YM; Chao HY; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
Zhonghua Nei Ke Za Zhi; 2009 Feb; 48(2):140-3. PubMed ID: 19549471
[TBL] [Abstract][Full Text] [Related]
29. Frequency of Janus associated kinase 2 (V617F) mutation in patients of polycythemia vera.
Khattak SA; Ahmed S; Anwar J; Bozdar M
J Coll Physicians Surg Pak; 2012 Feb; 22(2):80-3. PubMed ID: 22313642
[TBL] [Abstract][Full Text] [Related]
30. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alvarez-Larrán A; Angona A; Martínez-Avilés L; Bellosillo B; Besses C
Leuk Res; 2012 Mar; 36(3):324-6. PubMed ID: 22001278
[TBL] [Abstract][Full Text] [Related]
31. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].
Kerguelén Fuentes AE; Hernández-Maraver D; Lombardia L; Canales Albendea MA; Rodriguez de la Rúa A
Med Clin (Barc); 2012 Oct; 139(9):373-8. PubMed ID: 22743278
[TBL] [Abstract][Full Text] [Related]
32. Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia.
Godfrey AL; Chen E; Pagano F; Silber Y; Campbell PJ; Green AR
Haematologica; 2013 May; 98(5):718-21. PubMed ID: 23633544
[TBL] [Abstract][Full Text] [Related]
33. Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme.
Roda P; Ferrari A; Tang X; Erlich P; Eisenhower C; Patel MD; Irvin-Barnwell EA
Ann Hematol; 2014 Sep; 93(9):1467-72. PubMed ID: 24687383
[TBL] [Abstract][Full Text] [Related]
34. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
[TBL] [Abstract][Full Text] [Related]
35. Frequency of Zygosity in Jak-2 Positive Patients with Polycythemia Vera-Pakistan's Perspective.
Shah SZ; Raza N; Nasir MI; Zaidi SMH
Asian Pac J Cancer Prev; 2021 Feb; 22(2):559-564. PubMed ID: 33639674
[TBL] [Abstract][Full Text] [Related]
36. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
37. Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.
Tiziana Storlazzi C; Pieri L; Paoli C; Daniele G; Lasho T; Tefferi A; Vannucchi AM
Am J Hematol; 2014 Apr; 89(4):438-42. PubMed ID: 24382738
[TBL] [Abstract][Full Text] [Related]
38. JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV).
Mustjoki S; Borze I; Lasho TL; Alitalo R; Pardanani A; Knuutila S; Juvonen E
Leuk Res; 2009 Jan; 33(1):54-9. PubMed ID: 18760472
[TBL] [Abstract][Full Text] [Related]
39. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
[TBL] [Abstract][Full Text] [Related]
40. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]